Ligand Pharmaceuticals (LGND) Market Valuation Rose While Knott David M Cut Position by $4.78 Million; Starbucks (SBUX) Shareholder Caxton Associates LP Trimmed Stake by $7.84 Million as Share Price Rose

May 26, 2018 - By Nellie Frank

Starbucks Corporation (NASDAQ:SBUX) Logo

Bruce Kovner decreased its stake in Starbucks Corp (SBUX) by 68.75% based on its latest 2017Q4 regulatory filing with the SEC. Caxton Associates Lp sold 137,500 shares as the company’s stock rose 0.28% while stock markets declined. The hedge fund run by Bruce Kovner held 62,500 shares of the restaurants company at the end of 2017Q4, valued at $3.59M, down from 200,000 at the end of the previous reported quarter. Caxton Associates Lp who had been investing in Starbucks Corp for a number of months, seems to be less bullish one the $79.93 billion market cap company. The stock increased 0.42% or $0.24 during the last trading session, reaching $57.92. About 4.87 million shares traded. Starbucks Corporation (NASDAQ:SBUX) has risen 0.40% since May 26, 2017 and is uptrending. It has underperformed by 11.15% the S&P500.

Knott David M decreased its stake in Ligand Pharmaceuticals Incorporated (LGND) by 4.4% based on its latest 2017Q4 regulatory filing with the SEC. Knott David M sold 35,156 shares as the company’s stock rose 20.51% while stock markets declined. The institutional investor held 762,944 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $104.47M, down from 798,100 at the end of the previous reported quarter. Knott David M who had been investing in Ligand Pharmaceuticals Incorporated for a number of months, seems to be less bullish one the $4.04 billion market cap company. The stock decreased 0.09% or $0.17 during the last trading session, reaching $189.25. About 248,915 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since May 26, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

More notable recent Starbucks Corporation (NASDAQ:SBUX) news were published by: 247Wallst.com which released: “Is Starbucks Still at War With McDonald’s?” on April 27, 2018, also Seekingalpha.com with their article: “Starbucks: Buy Or Hold?” published on May 08, 2018, 247Wallst.com published: “6 Most Important Things in Business Today” on May 22, 2018. More interesting news about Starbucks Corporation (NASDAQ:SBUX) were released by: Seekingalpha.com and their article: “Not A Venti Quarter At Starbucks” published on April 30, 2018 as well as Seekingalpha.com‘s news article titled: “Starbucks opens bathrooms to everyone” with publication date: May 21, 2018.

Investors sentiment increased to 1.05 in 2017 Q4. Its up 0.08, from 0.97 in 2017Q3. It improved, as 63 investors sold SBUX shares while 449 reduced holdings. 114 funds opened positions while 423 raised stakes. 983.38 million shares or 1.10% more from 972.68 million shares in 2017Q3 were reported. Moreover, C Gru A S has 0.69% invested in Starbucks Corporation (NASDAQ:SBUX) for 835,295 shares. Earnest Limited Com invested in 694 shares. Amf Pensionsforsakring accumulated 1.46 million shares. Intersect Cap Ltd Llc stated it has 0.23% of its portfolio in Starbucks Corporation (NASDAQ:SBUX). Verition Fund Limited Liability Corporation holds 0.1% or 18,676 shares in its portfolio. Inv Advisors Limited Liability Corp stated it has 5,785 shares. National Bank & Trust Pictet Cie (Asia) Limited holds 1.63% or 65,622 shares. The California-based Sand Hill Global Advsr Ltd Liability Com has invested 0.06% in Starbucks Corporation (NASDAQ:SBUX). Eaton Vance owns 0.71% invested in Starbucks Corporation (NASDAQ:SBUX) for 5.11M shares. Balasa Dinverno Foltz Ltd Liability invested in 11,364 shares. Hoertkorn Richard Charles invested 1.81% in Starbucks Corporation (NASDAQ:SBUX). Gradient Limited Company reported 2,041 shares. Motco holds 75,349 shares or 0.44% of its portfolio. Fuller And Thaler Asset Mgmt stated it has 9,400 shares. Wells Fargo Com Mn stated it has 9.29 million shares or 0.15% of all its holdings.

Caxton Associates Lp, which manages about $10.75 billion and $2.03B US Long portfolio, upped its stake in Check Point Software Tech Lt (NASDAQ:CHKP) by 5,185 shares to 10,585 shares, valued at $1.10M in 2017Q4, according to the filing. It also increased its holding in Select Sector Spdr Tr (Put) (XLU) by 150,000 shares in the quarter, for a total of 300,000 shares, and has risen its stake in Overseas Shipholding Group I.

Analysts await Starbucks Corporation (NASDAQ:SBUX) to report earnings on July, 26. They expect $0.65 EPS, up 18.18% or $0.10 from last year’s $0.55 per share. SBUX’s profit will be $897.00M for 22.28 P/E if the $0.65 EPS becomes a reality. After $0.53 actual EPS reported by Starbucks Corporation for the previous quarter, Wall Street now forecasts 22.64% EPS growth.

Since January 31, 2018, it had 0 buys, and 3 selling transactions for $13.62 million activity. 59,838 Starbucks Corporation (NASDAQ:SBUX) shares with value of $3.60 million were sold by WEATHERUP CRAIG. $9.28M worth of Starbucks Corporation (NASDAQ:SBUX) was sold by BURROWS CLIFFORD on Wednesday, January 31.

Among 37 analysts covering Starbucks Corporation (NASDAQ:SBUX), 23 have Buy rating, 0 Sell and 14 Hold. Therefore 62% are positive. Starbucks Corporation had 107 analyst reports since July 28, 2015 according to SRatingsIntel. Deutsche Bank maintained it with “Hold” rating and $59 target in Wednesday, November 2 report. The rating was maintained by Wedbush on Wednesday, September 28 with “Outperform”. OTR Global downgraded the shares of SBUX in report on Wednesday, July 13 to “Mixed” rating. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, October 19. The rating was initiated by Buckingham Research with “Neutral” on Monday, November 21. Wedbush maintained it with “Outperform” rating and $65 target in Monday, March 13 report. The stock of Starbucks Corporation (NASDAQ:SBUX) has “Hold” rating given on Friday, July 28 by Stephens. Cowen & Co maintained Starbucks Corporation (NASDAQ:SBUX) rating on Friday, January 19. Cowen & Co has “Buy” rating and $68.0 target. UBS maintained it with “Buy” rating and $64.0 target in Friday, November 3 report. The firm earned “Buy” rating on Monday, May 21 by UBS.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on August, 6. They expect $0.82 EPS, up 51.85% or $0.28 from last year’s $0.54 per share. LGND’s profit will be $17.48 million for 57.70 P/E if the $0.82 EPS becomes a reality. After $1.38 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -40.58% negative EPS growth.

Investors sentiment decreased to 1.25 in 2017 Q4. Its down 0.44, from 1.69 in 2017Q3. It turned negative, as 21 investors sold LGND shares while 86 reduced holdings. 31 funds opened positions while 103 raised stakes. 22.68 million shares or 0.37% less from 22.76 million shares in 2017Q3 were reported. Mason Street accumulated 5,489 shares. Comerica National Bank has 0.03% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Kopp Invest Limited Liability Company invested in 22,026 shares. First Light Asset Lc stated it has 4.2% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Lpl Financial Llc holds 0% or 4,078 shares in its portfolio. Sei Investments Company invested in 10,857 shares. Loomis Sayles Co Limited Partnership accumulated 278 shares or 0% of the stock. Kennedy Capital Mngmt invested 0.11% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Bartlett And Ltd Co reported 33 shares. Tiaa Cref Inv Mgmt Lc reported 56,185 shares. The Illinois-based Peak6 Limited Partnership has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Us National Bank & Trust De reported 10,978 shares or 0% of all its holdings. Parametric Portfolio Assoc Limited Company has 185,926 shares. Osterweis Capital Mgmt owns 34,624 shares or 0.34% of their US portfolio. 6,591 were accumulated by Metropolitan Life Ins Ny.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 29 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Sell” rating by Deutsche Bank given on Monday, November 20. The stock has “Hold” rating by Deutsche Bank on Tuesday, August 8. The firm has “Buy” rating given on Friday, December 18 by Roth Capital. Roth Capital maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Monday, September 21 with “Buy” rating. Deutsche Bank downgraded the stock to “Sell” rating in Friday, August 5 report. H.C. Wainwright maintained it with “Buy” rating and $182 target in Wednesday, March 7 report. As per Wednesday, April 13, the company rating was initiated by Stephens. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by H.C. Wainwright on Wednesday, October 5. TH Capital maintained the shares of LGND in report on Wednesday, September 30 with “Buy” rating. As per Thursday, November 9, the company rating was maintained by H.C. Wainwright.

Knott David M, which manages about $251.42 million US Long portfolio, upped its stake in Macquarie Infrastructure Corporation (NYSE:MIC) by 120,000 shares to 132,300 shares, valued at $8.49 million in 2017Q4, according to the filing.

Since December 20, 2017, it had 0 insider purchases, and 14 insider sales for $20.00 million activity. KOZARICH JOHN W sold $362,500 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, January 10. 22,500 shares were sold by HIGGINS JOHN L, worth $3.71M. Aryeh Jason sold $529,635 worth of stock. Another trade for 925 shares valued at $126,956 was made by Sabba Stephen L on Wednesday, December 20. $832,824 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by FOEHR MATTHEW W. The insider Davis Todd C sold $2.62M.

More important recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Streetinsider.com which released: “Ligand Pharma (LGND) Tops Q1 EPS by 40c” on May 08, 2018, also Streetinsider.com published article titled: “Ligand Pharma (LGND) Proposed Offering of $650M of Convertible Senior Notes”, Seekingalpha.com published: “Xeris Pharmaceuticals on deck for IPO” on May 25, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was released by: Globenewswire.com and their article: “New Research Coverage Highlights Assurant, Williams Partners, Atmos Energy, Nationstar Mortgage, Applied …” with publication date: May 15, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: